Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.

Blood·2026
Same author

Optimizing methods for virome analysis based on studies of a synthetic viral community.

mSystems·2026
Same author

LVV SMRTcap reveals extensive proviral variation in lentiviral vector-transduced CAR T cells.

bioRxiv : the preprint server for biology·2026
Same author

Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery.

The New England journal of medicine·2026
Same author

Uncovering viral protein acquisition events and human-specific folds with pairwise comparisons of predicted protein structures.

Molecular biology and evolution·2026
Same author

The naked mole-rat microbiome is associated with healthy aging and social structure.

Cell reports·2026
Same journal

HIV-related stigma, antiretroviral adherence, and viral suppression among women with HIV: the role of anxiety and patient-provider relationship.

AIDS (London, England)·2026
Same journal

Impact of influenza and pneumococcal vaccines on inflammatory response during suppressive antiretroviral therapy.

AIDS (London, England)·2026
Same journal

CD4+ cell count trends after common cancers in people with HIV: a multicohort collaboration.

AIDS (London, England)·2026
Same journal

HIV-1 soluble gp120 in cerebrospinal fluid is associated with poorer motor domain neurocognitive performance in virally suppressed people with HIV.

AIDS (London, England)·2026
Same journal

Vascular risk drives cognitive decline over 10 years in people aging with well-controlled HIV.

AIDS (London, England)·2026
Same journal

Hazardous alcohol use, sexual behavior, and recent and undiagnosed HIV across 11 Eastern and Southern African countries.

AIDS (London, England)·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Switching between raltegravir resistance pathways analyzed by deep sequencing.

Rithun Mukherjee1, Shane T Jensen, Frances Male

  • 1Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, USA.

AIDS (London, England)
|August 12, 2011
PubMed
Summary
This summary is machine-generated.

HIV integrase inhibitor resistance pathways were analyzed. Major drug resistance mutations were rarely detected before treatment, with complex mutation pathways observed during therapy.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Amplicon Sequencing using the Long-Read Sequencing Technologies
08:57

Amplicon Sequencing using the Long-Read Sequencing Technologies

Published on: August 29, 2025

Related Experiment Videos

Last Updated: May 30, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Amplicon Sequencing using the Long-Read Sequencing Technologies
08:57

Amplicon Sequencing using the Long-Read Sequencing Technologies

Published on: August 29, 2025

Area of Science:

  • Virology
  • Molecular Biology
  • Genetics

Background:

  • HIV integrase inhibitors (INIs) are crucial for antiretroviral therapy.
  • Understanding resistance pathways is vital for optimizing HIV treatment strategies.
  • Raltegravir (RAL) is a commonly used integrase inhibitor.

Purpose of the Study:

  • To analyze the evolutionary pathways of HIV resistance to the integrase inhibitor raltegravir (RAL).
  • To identify the prevalence of drug resistance mutations (DRMs) prior to therapy.
  • To characterize complex mutation pathways and recombination events during RAL resistance development.

Main Methods:

  • Longitudinal analysis of viral samples from three HIV-infected individuals.
  • Deep sequencing (454/Roche pyrosequencing) of the HIV integrase coding region.
  • Viral serial pathway analysis (vSPA) for quantitative modeling of viral lineages and error correction using Pyronoise.

Main Results:

  • All patients exhibited pathway switching from N155H to Q148H/G140S.
  • vSPA revealed complex mutation pathways, likely involving de novo mutation and recombination.
  • The double mutant (N155H and Q148H) was not detected, suggesting low fitness.
  • Major DRMs were generally absent or at very low levels before treatment initiation.

Conclusions:

  • Pre-existing major drug resistance mutations (DRMs) are typically at very low levels before initiating HIV therapy.
  • Complex mutation and recombination pathways contribute to the development of RAL resistance.
  • The study provides a framework for deep sequence analysis of DRMs in longitudinal HIV samples.